| scholarly article | Q13442814 |
| P50 | author | S H Ghaffari | Q70757933 |
| P2093 | author name string | Ardeshir Ghavamzadeh | |
| Kamran Alimoghaddam | |||
| Shahin Ahmadian | |||
| Ali Khaleghian | |||
| P2860 | cites work | The methyl-CpG binding protein MBD1 is required for PML-RARalpha function | Q24301882 |
| Differential methylation of the arsenic (III) methyltransferase promoter according to arsenic exposure | Q28397251 | ||
| Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. | Q31808367 | ||
| Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. | Q33551142 | ||
| Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data | Q33636371 | ||
| Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide | Q34032925 | ||
| PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. | Q34099047 | ||
| Histone deacetylase inhibitors: novel anticancer agents | Q34119504 | ||
| Upregulation of glutathione-related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. | Q34159920 | ||
| DNA methylation: superior or subordinate in the epigenetic hierarchy? | Q34218919 | ||
| Histone deacetylase as a new target for cancer chemotherapy. | Q34392069 | ||
| The cellular metabolism and systemic toxicity of arsenic | Q34401625 | ||
| Efficient arsenic metabolism--the AS3MT haplotype is associated with DNA methylation and expression of multiple genes around AS3MT. | Q34558657 | ||
| Involvement of N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) in arsenic biomethylation and its role in arsenic-induced toxicity | Q35044729 | ||
| Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215) | Q36054468 | ||
| shRNA silencing of AS3MT expression minimizes arsenic methylation capacity of HepG2 cells | Q36579671 | ||
| Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin | Q36938551 | ||
| Metabolism and the paradoxical effects of arsenic: carcinogenesis and anticancer | Q37264774 | ||
| Arsenite alters global histone H3 methylation | Q37294622 | ||
| Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia | Q37307720 | ||
| Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. | Q37392124 | ||
| Metabolism of arsenic in human liver: the role of membrane transporters | Q37658372 | ||
| Acute promyelocytic leukaemia: novel insights into the mechanisms of cure | Q37802188 | ||
| Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest | Q39156125 | ||
| Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription | Q39286256 | ||
| Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. | Q39445570 | ||
| Arsenic metabolism in multiple myeloma and astrocytoma cells | Q40106628 | ||
| Long term low-dose arsenic exposure induces loss of DNA methylation | Q40208257 | ||
| Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. | Q40292872 | ||
| Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids | Q40394694 | ||
| Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines | Q40647347 | ||
| Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells | Q40788118 | ||
| Arsenic compound-induced increases in glutathione levels in cultured Chinese hamster V79 cells and mechanisms associated with changes in gamma-glutamylcysteine synthetase activity, cystine uptake and utilization of cysteine | Q41137016 | ||
| Glutathione-dependent reduction of arsenate in human erythrocytes--a process independent of purine nucleoside phosphorylase | Q42468838 | ||
| Differential response of cellular antioxidant mechanism of liver and kidney to arsenic exposure and its relation to dietary protein deficiency | Q43507311 | ||
| Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in v | Q43878427 | ||
| Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells | Q44349057 | ||
| Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells | Q44666108 | ||
| Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment | Q44731642 | ||
| A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. | Q45139003 | ||
| Stability of arsenic metabolites, arsenic triglutathione [As(GS)3] and methylarsenic diglutathione [CH3As(GS)2], in rat bile | Q46465420 | ||
| Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy | Q46755203 | ||
| Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. | Q53984630 | ||
| Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. | Q54367099 | ||
| Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells | Q56114256 | ||
| P433 | issue | 10 | |
| P921 | main subject | acute promyelocytic leukemia | Q612108 |
| P304 | page(s) | 1729-1739 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | Journal of Cellular Biochemistry | Q6294917 |
| P1476 | title | Metabolism of arsenic trioxide in acute promyelocytic leukemia cells | |
| P478 | volume | 115 |
| Q41681199 | Arsenic (+3 oxidation state) methyltransferase is a specific but replaceable factor against arsenic toxicity. |
| Q37407152 | Deficiency of SUMO-specific protease 1 induces arsenic trioxide-mediated apoptosis by regulating XBP1 activity in human acute promyelocytic leukemia |
| Q91992770 | Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity |
| Q36413252 | Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation |
| Q33649020 | Oncogenomic disruptions in arsenic-induced carcinogenesis |
| Q48266344 | Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4). |
Search more.